ClinicalTrials.gg
Not yet recruitingNCT07845721Updated Nov 3, 2026

Using Contact Lenses and Spectacle Lenses as Myopia Interventions.

An interventional study of Test Spectacle Lens & Contact Lens and Control Spectacle Lens & Contact Lens in Myopia, sponsored by CooperVision International Limited (CVIL). Not yet recruiting at 2 sites in 2 countries. Open to participants aged 11 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by CooperVision International Limited (CVIL) (part of CooperCompanies) · Not applicable, Interventional, and Treatment

Updated Nov 3, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
11 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 117 studies in Myopia by CooperCompanies — 7 open to participants now, 9 under way, none of them phase 3. Myopia · CooperCompanies.

Planned enrollment
45th of 116
58 · median 50
Started
2026
with 5 others
No phase
116 of 117
7 open now
Registered
115th of 117
by date

Among the 117 studies in Myopia by CooperCompanies, this one is the 45th largest by planned enrollment of the 116 interventional ones that give a count, is one of 6 that started in 2026, is one of 116 with no phase, and was the 115th registered.

Myopia

1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

7 of the 117 studies in Myopia by CooperCompanies are open now, in 6 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.

This study: 11 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 117 studies in Myopia by CooperCompanies, or all of them as a file.
02

Study summary

Effect of alternating contact lenses and spectacles for myopia control.

03

Conditions studied

  • Myopia

Browse trials for

04

Who can participate

Ages eligible
11 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are aged 11 to 17 years (inclusive);
  • Have successfully completed the 4-year MiSight® Analysis of Progression (MAP) Study;
  • Are established soft contact lens wearers (including myopia control contact lens designs);
  • Have read and signed the study consent or assent form, as appropriate for their age;
  • Have a parent or legal guardian who has read and signed the Parent/Guardian Information Sheet (PIS) and Consent Form;
  • Are willing and able to follow study instructions and maintain the appointment schedule;
  • Are willing to wear the study contact lenses for 10 hours/day and 5 days per week as an ideal target while participating;
  • Require a spherical contact lens power correction between -0.50 and -6.00 D;
  • Have astigmatism not exceeding 2.00 DC in each eye by subjective refraction;
  • Have best-corrected visual acuity of 0.10 logMAR (approx. 20/25 Snellen) or better in each eye;
  • Have ocular health findings (biomicroscopy) that do not contraindicate contact lens wear;
  • Continue to demonstrate acceptable fit and handling with the study contact lenses.

Exclusion criteria

Exclusion Criteria:

  • Are participating in any concurrent clinical or interventional study;
  • Have worn rigid gas-permeable (including orthokeratology) contact lenses within the previous 30 days;
  • Have used atropine concentrations above 0.01% for myopia control in the previous 30 days;
  • Are extended-wear contact lens users (i.e., sleep in their lenses);
  • Have best-corrected visual acuity worse than 0.10 logMAR in either eye;
  • Have any current or evolving ocular or systemic condition that could affect visual function, ocular growth, or contact lens wear;
  • Have any corneal or conjunctival staining with sodium fluorescein, or other ocular findings contraindicating contact lens wear;
  • Are using systemic or topical medications known or expected to affect pupil size, tear production, accommodation, refractive state, or any study outcome variable;
  • Have a history of ocular surgery, keratoconus, or other forms of irregular cornea, or are aphakic;
  • Have diagnosed accommodative and/or binocular vision anomalies, including amblyopia, strabismus, or nystagmus;
  • Have known sensitivity or allergy to any of the diagnostic agents used in the study;
  • Have any systemic condition that, in the opinion of the investigator, may influence study outcomes or contraindicate soft contact lens wear, including pregnancy;
  • Are a child of an employee of either clinical site directly involved in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    Test Group

    Participants will wear Test Spectacle Lens \& Contact Lenses

    Device: Test Spectacle Lens & Contact Lens

  • Experimental
    Control Group

    Participants will wear Control Spectacle Lens \& Contact Lenses

    Device: Control Spectacle Lens & Contact Lens

Interventions

  • DeviceTest Spectacle Lens & Contact Lens

    Participants will wear contact lenses for a target of 10 hours a day, 5 days per week and test spectacle lenses for remaining waking hours.

  • DeviceControl Spectacle Lens & Contact Lens

    Participants will wear contact lenses for a target of 10 hours a day, 5 days per week and control spectacle lenses for remaining waking hours.

06

What researchers measure

Primary outcomes

  1. Change in axial length (AXL, mm) over 12 months

    Time frame: Over 12 months

07

Study locations

2 sites
  • Centre for Ocular Research & Education (CORE) School of Optometry & Vision Science University of Waterloo
    Waterloo, Ontario N2L 3Gi, Canada
    • Jill Woods · Contactjwoods@uwaterloo.ca · 1-519 888 4567 ext 436743
    • Jill Woods · Principal investigator
    • Deborah Jones · Principal investigator
  • Aston University
    Birmingham, B4 7ET, United Kingdom
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Feb 2028, 14 months later.

Of 234 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's planned 14 months is above that.

Counting every sponsor, half of 434 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 29, 2026
StartEst.
Dec 2026was Sep 2026
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Dec 2026
Nov 3, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 2 updates
  1. Nov 3, 2026
    Start date Sep 2026→Dec 2026
    + 1 other change: verification date
  2. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07845721
Collaborators
SightGlass Vision, Inc.
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Dec 2026 (estimated)
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Baskar Arumugam, PhD
Contact
barumugam@coopervision.com
1(925) 353-8468
Baskar Arumugam, PhD
study chair · CooperVision, Inc.
Debbbie Laughton
study chair · SightGlass Vision, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion